Industry context
Tempus AI Inc [TEM]
Last Updated 25 Jun 2026 @ 16:00 (Exchange is closed)
Last: $54.87
5.64%
2.65 (↑)
GaG Algo Score™
v1.0
Short
2.65 (↑)
Medium
2.06 (↑)
Long
1.53 (↑)
BUY
64.00%
return 2.75%
SELL
61.22%
return 3.10%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 22.17% | 19.10% | 6.71% |
| Loss % | -25.50% | -26.01% | 8.07% |
| Duration | 21.8d | 21d | 13.3d |
| Total Pivots Found | 12 |
| Gain/Loss Legs | 11 (5 Gain / 6 Loss) |
| Last Pivot | Bottom @ $46.43 on 2026-06-05 |
| Change since Last Pivot | $8.44 (18.18%) |
Next Pivot Prediction Last: $54.87
| Predicted Next Type | Top |
| Predicted Price (Avg) | $56.73 |
| Predicted Price (Median) | $55.30 |
| Predicted Price Range (~68%) | $53.61 - $59.84 |
| Change to Avg Target | $1.86 (3.38%) |
| Predicted Date (Avg) | 2026-06-26 |
| Predicted Date Range (~68%) | 2026-06-13 - 2026-07-10 |
| Basis | Based on 5 historical gains (Avg: 22.17%, Median: 19.10%, StdDev: 6.71%) and duration (Avg: 21.8 days, StdDev: 13.3 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
TEM surges on on above-average volume.
Tempus AI Inc (TEM) stock price surged on Thursday after the stock rose $2.93 (5.64%) from the previous session on above-average volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.46%.(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) Yesterday's trading volume was 9.25M shares, worth about $507.56M. This represents 2.28M shares more than the day before. Volume was above the 10-day average of 6.66M shares.
Tempus AI Inc signals
There is no conclusive signals given from RSI. The price is above both moving averages, but the short-term average remains below the long-term average; upward momentum is present but not yet fully confirmed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (23.3%), medium- (23.3%), and long-term (23.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Tempus AI Inc Support & Resistance Levels
The stock is trading above the closest support level at $53.20. approximately $1.670 (3.04%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s153.2 -
Tempus AI Inc Evaluation
- Short score: 2.65
- Medium score: 2.06
- Long score: 1.53
Ownership flow
GetAGraph InsiderPower
Transactions
456
Buy power
64.73M
Sell power
516.09M
Reliability
100/100
Buy / sell
0.13
Hist. corr.
-0.72
Latest signal
Sell 2026-06-05
Executive 218
Officer 176
Director 62
2026-06-01
Epstein David R Director
Sell 250
2026-05-27
Lefkofsky Eric P Executive
Sell 35 721
2026-05-27
Lefkofsky Eric P Executive
Sell 97 279
2026-05-27
Lefkofsky Eric P Executive
Sell 8 932
2026-05-27
Lefkofsky Eric P Executive
Sell 24 318
2026-05-27
Lefkofsky Eric P Executive
Sell 8 932
Relationship map
Correlation snapshot
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>3.05% <strong>$56.58</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
18.15%
Of outstanding shares
Short float
27.80%
Of tradable float
Days to cover
5.20
Short interest divided by average volume
Squeeze probability
99.70%
-11.48% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
11
EPS beats
2
EPS misses
2
Avg. surprise
-2.41%
Tempus AI Inc Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Waiting
Q1/2023
Waiting
Q2/2023
Waiting
Q3/2023
Waiting
Q4/2023
Waiting
Q1/2024
Miss
Q2/2024
Beat
Q3/2024
Miss
Q4/2024
Beat
Q1/2025
Waiting
Q2/2025
Tempus AI Inc Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-08-05 | Q2/2025 | $-0.210 | - | Waiting | 296.84M | - | Waiting |
| 2025-05-06 | Q1/2025 | $-0.270 | $-0.240 | Beat 11.11% | 248.13M | 255.74M | Beat 3.07% |
| 2025-02-24 | Q4/2024 | $-0.150 | $-0.180 | Miss -20.00% | 248.84M | 200.68M | Miss -19.36% |
| 2024-11-04 | Q3/2024 | $-0.266 | $-0.250 | Beat 6.04% | 179.52M | 180.93M | Beat 0.78% |
| 2024-08-06 | Q2/2024 | $-0.590 | $-0.630 | Miss -6.78% | 179.52M | 165.97M | Miss -7.55% |
| 2024-06-17 | Q1/2024 | - | $-0.381 | Waiting | - | 145.82M | Waiting |
| 2023-12-30 | Q4/2023 | - | $-0.297 | Waiting | - | 147.72M | Waiting |
| 2023-09-29 | Q3/2023 | - | $-0.315 | Waiting | - | 136.06M | Waiting |
| 2023-06-29 | Q2/2023 | - | $-0.329 | Waiting | - | 132.42M | Waiting |
| 2023-03-30 | Q1/2023 | - | $-0.320 | Waiting | - | 115.62M | Waiting |
| 2022-12-29 | ~2022 Q4? | - | $-0.389 | Waiting | - | 100.63M | Waiting |
| 2021-12-29 | ~2021 Q4? | - | $-0.347 | Waiting | - | 73.31M | Waiting |
Analyst view
Analyst targets
Consensus
$72.60
Median
$64.00
Low
$59.00
High
$100.00
Recent target updates
News flow
Latest company news
Market coverage
businesswire.com Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers Jun 25, 2026 zacks.com Should You Retain Tempus AI Stock In Your Portfolio Now? Jun 18, 2026 fxempire.com Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms Jun 16, 2026 seekingalpha.com Tempus AI: AI Precision Medicine With A Moat Jun 11, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Technology
Industry:
Software Application
Currency
USD
Tempus AI Inc operates as a healthcare technology company in the United States It offers the Tempus platform a closedloop fullstack bidirectional integrations between a clinicians desktop and its laboratory diagnostic capabilities analytics platform and repository of multimodal data and Hub a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an endtoend application for healthcare providers for NGS tests The company also provides Lens a software application for life sciences and advanced precision research diagnostics services such as NGS diagnostics PCR profiling and other anatomic and molecular pathology tests and largepanel solid tumor and hematologic testing through multiple assays with its core clinical assay xT and xR offering large panel DNA RNA full transcriptome and incidental germline findings through normal blood or saliva analyses In addition it provides genetic tests focused on inherited conditions an nP assay for pharmacogenomic testing for patients with psychiatric conditions including depression general anxiety disorder bipolar disorder and other relevant diagnoses Insights which licenses libraries of linked deidentified clinical molecular and imaging data Organoids a tumor derived biological modeling Further the company offers Trials for clinical trial matching services Next an AI platform Algos an algorithmbased diagnostics application It has Strategic Collaborations with AstraZeneca AB Pathos AI Inc GlaxoSmithKline Merck and Recursion Pharmaceuticals Inc Additionally it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia The company was formerly known as Tempus Labs Inc and changed its name to Tempus AI Inc in January 2023 Tempus AI Inc was incorporated in 2015 and is headquartered in Chicago Illinois
Navigation